GlaxoSmithKline's Buy Is No Snore

Picking up the maker of Breathe Right nasal products will be additive, no matter what.
Publish date:

This column was originally published on RealMoney on Oct. 9 at 11:57 a.m. EDT. It's being republished as a bonus for readers.



(GSK) - Get Report

continues to make every right move. You may think buying Breathe Right nasal goods and assorted other products seems knuckleheaded, especially if you have never used some of them. But all of these snore products, as well as some fiber products, are deeply embedded in drugstore aisles, which makes this GlaxoSmithKline deal additive, no matter what.

Remember, GlaxoSmithKline is


(PEP) - Get Report

for the drug store, buying up generic aisle space and running it through the distribution pipe. We know that this acquisition and all the others are very important, because we saw the billion dollars

Johnson & Johnson

(JNJ) - Get Report

had to pay to get


(PFE) - Get Report

generic -- over-the-counter goods.

GlaxoSmithKline's a really smart company with great management. The combination of the 3% yield and the 15 multiple makes it one of the top pharma choices for a slowing economy.

At the time of publication, Cramer was long Johnson & Johnson.

Jim Cramer is a director and co-founder of He contributes daily market commentary for's sites and serves as an adviser to the company's CEO. Outside contributing columnists for and, including Cramer, may, from time to time, write about stocks in which they have a position. In such cases, appropriate disclosure is made. To see his personal portfolio and find out what trades Cramer will make before he makes them, sign up for

Action Alerts PLUS. Listen to Cramer's RealMoney Radio show on your computer; just click

here. Watch Cramer on "Mad Money" at 6 p.m. ET weeknights on CNBC. Click

here to order Cramer's latest book, "Real Money: Sane Investing in an Insane World," click

here to get his second book, "You Got Screwed!" and click

here to order Cramer's autobiography, "Confessions of a Street Addict." While he cannot provide personalized investment advice or recommendations, he invites you to send comments on his column by

clicking here. has a revenue-sharing relationship with Traders' Library under which it receives a portion of the revenue from Traders' Library purchases by customers directed there from